Cosmetic cross-reference Noindex: medium evidence

Ciaftalan

CAS 574-93-6

Ciaftalan (CAS 574-93-6) is a Phase 1 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Ciaftalan
CAS Number
574-93-6
UNII
V5PUF4VLGY
InChIKey
IEQIEDJGQAUEQZ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL262101
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 1
Early-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL262101 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ciaftalan used for in pharmaceutical contexts?

Ciaftalan (CAS 574-93-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ciaftalan?

No adverse-event association or SIDER side-effect rows are rendered for Ciaftalan in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ciaftalan also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for CI 74100 with EU status "permitted".

What clinical phase is Ciaftalan in?

Ciaftalan is rendered with ChEMBL max phase 1.